Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 513 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infection, Human Immunodeficiency Virus I Clear all
Completed Phase 1 Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

NCT00001062
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

NCT00000810
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Not applicable Interventional

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection

NCT00000995
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Zidovudine, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
3
States / cities
San Diego, California • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

NCT00012519
View directory record Official record
Conditions
HIV Infections
Interventions
indinavir sulfate, ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Phase 1 Safety Study of Two Experimental HIV Vaccines

NCT00479999
View directory record Official record
Conditions
AIDS Vaccines, HIV Infections, HIV-1
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

NCT00001088
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-047, Bupivacaine hydrochloride
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 13, 2026, 9:45 PM EDT
Terminated Phase 2 Interventional Results available

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

NCT06005610
View directory record Official record
Conditions
HIV I Infection
Interventions
Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 13, 2026, 9:45 PM EDT
Active, not recruiting Phase 1 Interventional

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

NCT04340596
View directory record Official record
Conditions
HIV Infection
Interventions
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients

NCT00002350
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-003
Biological
Lead sponsor
Apollon
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of BufferGel in Women

NCT00000927
View directory record Official record
Conditions
HIV Infections
Interventions
BufferGel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 9, 2007 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

NCT00321061
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

NCT00002262
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tumor Necrosis Factor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

NCT00002218
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

A Study of DPC 817 in HIV-Infected Males

NCT00040274
View directory record Official record
Conditions
HIV Infections
Interventions
DPC 817
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

NCT01734850
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
Drug · Biological
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

NCT00002096
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Zidovudine, Didanosine, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Irvine, California • Washington D.C., District of Columbia • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

NCT00002008
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Sargramostim
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

NCT00102089
View directory record Official record
Conditions
Healthy, HIV Infections
Interventions
VRC-HIVADV014-00-VP booster, VRC-HIVADV014-00-VP
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

NCT00000692
View directory record Official record
Conditions
HIV Infections
Interventions
Butyldeoxynojirimycin
Drug
Lead sponsor
G D Searle
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Diego, California • Stanford, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

NCT00027365
View directory record Official record
Conditions
HIV Infections
Interventions
Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A, NefTat, AS02A Adjuvant, gp120W61D
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

NCT01495598
View directory record Official record
Conditions
Kaposi Sarcoma, Sarcoma, Kaposi
Interventions
Pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

NCT00000971
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Zidovudine, Didanosine
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Months to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 13, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

NCT00000695
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon beta-1b, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 13, 2026, 9:45 PM EDT